- Home
- Publications
- Publication Search
- Publication Details
Title
Trial Watch: Monoclonal antibodies in cancer therapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 1, Issue 1, Pages 28-37
Publisher
Informa UK Limited
Online
2012-01-03
DOI
10.4161/onci.1.1.17938
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)
- (2012) Diane Seimetz Journal of Cancer
- Trials Define Anti-Tumor Effects of Anti-Resorptive Agents†
- (2011) Ben Weintraub BIODRUGS
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
- (2011) Sally A. Hunsucker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Modulation of tumor immunity by therapeutic monoclonal antibodies
- (2011) Riad Abès et al. CANCER AND METASTASIS REVIEWS
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
- (2011) Oliver Kepp et al. CANCER AND METASTASIS REVIEWS
- Preclinical Evaluation of 177Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor–Overexpressing Tumors
- (2011) Denis Rolando Beckford Vera et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains
- (2011) Hiroaki Nagashima et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- CD30: an important new target in hematologic malignancies
- (2011) Yehuda E. Deutsch et al. LEUKEMIA & LYMPHOMA
- JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
- (2011) L. Song et al. MOLECULAR CANCER THERAPEUTICS
- Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice
- (2011) Elena Stylianou et al. VACCINE
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α
- (2010) Gaurav D. Shah et al. CANCER
- Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma
- (2010) Angel Casaco et al. CANCER BIOLOGY & THERAPY
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
- (2010) T. Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)
- (2010) Sara A. Hurvitz et al. Clinical Breast Cancer
- Targeting the Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
- (2010) M. R. Russell et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
- (2010) B. Kuenen et al. CLINICAL CANCER RESEARCH
- Novel Bone-Targeted Strategies in Oncology
- (2010) S. Vallet et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
- (2010) T. Puchalski et al. CLINICAL CANCER RESEARCH
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague
- (2010) Yoonkyung Do et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
- (2010) Stephen M Ansell EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
- (2010) Magdalena Winiarska Frontiers in Bioscience-Landmark
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
- (2010) R. Schoffelen et al. JOURNAL OF NUCLEAR MEDICINE
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model
- (2010) N. V. Rajeshkumar et al. MOLECULAR CANCER THERAPEUTICS
- Ofatumumab
- (2010) Michael J. Keating et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy
- (2010) Robert M. Sharkey et al. SEMINARS IN NUCLEAR MEDICINE
- Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications
- (2010) Luana Calabrò et al. SEMINARS IN ONCOLOGY
- Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor
- (2009) Jerry Y. Hsu et al. BIODRUGS
- 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma
- (2009) A. K. Gopal et al. BLOOD
- Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death
- (2009) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Complement and its role in innate and adaptive immune responses
- (2009) Jason R Dunkelberger et al. CELL RESEARCH
- Cixutumumab
- (2009) Kevin P McKian et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
- (2009) Cornelia Haas et al. IMMUNOBIOLOGY
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
- (2009) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
- (2009) P. J. Beltran et al. MOLECULAR CANCER THERAPEUTICS
- Glycosylation as a strategy to improve antibody-based therapeutics
- (2009) Roy Jefferis NATURE REVIEWS DRUG DISCOVERY
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes
- (2008) A. Yada et al. ANNALS OF ONCOLOGY
- Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
- (2008) Y Akashi et al. BRITISH JOURNAL OF CANCER
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
- FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients
- (2008) Márcia Paiva et al. CANCER GENETICS AND CYTOGENETICS
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
- (2008) G Kroemer et al. CELL DEATH AND DIFFERENTIATION
- Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
- (2008) L. M. Weiner et al. CLINICAL CANCER RESEARCH
- Targeting TRAIL death receptors
- (2008) CNAM Oldenhuis et al. CURRENT OPINION IN PHARMACOLOGY
- Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response
- (2008) Lydie Cassard et al. INTERNATIONAL JOURNAL OF CANCER
- Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
- (2008) Peter S. Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
- (2008) David Sancho et al. JOURNAL OF CLINICAL INVESTIGATION
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response
- (2008) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More